GlassScriptPhysician profile
Chetana Rondla
NPI 1417101189
$2,884.04
in general payments reported to CMS, 2019-2025
24 companies · $463 in 2025
The $463 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $402 · 2021: $323 · 2022: $500 · 2023: $476 · 2024: $501 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,402 · Education: $38.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.99 |
| Education | $38.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $340.24 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $315.21 | 2019-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $227.97 | 2019-2025 | Velphoro, Velphoro |
| Vifor Pharma, INC. | $210.57 | 2019-2022 | |
| Amgen INC. | $190.01 | 2021-2025 | Tavneos |
| Akebia Therapeutics INC | $187.06 | 2019-2024 | Vafseo, Auryxia |
| Glaxosmithkline, LLC. | $168.25 | 2020-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $165.18 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $130.04 | 2020-2025 | Acthar |
| Travere Therapeutics, INC. | $129.32 | 2020-2025 | |
| Outset Medical INC | $125.00 | 2023 | |
| Genzyme Corporation | $111.36 | 2019-2024 | |
| Calliditas Therapeutics US INC. | $96.27 | 2023-2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $91.12 | 2021-2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $72.92 | 2021-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $61.26 | 2019-2023 | Renal - Pd |
| Ardelyx, INC. | $58.67 | 2023-2025 | Ibsrela |
| Daiichi Sankyo INC. | $44.81 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $42.22 | 2022-2025 | Lupkynis |
| Opko Pharmaceuticals, LLC | $28.57 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.11 | 2020 | |
| Novartis Pharmaceuticals Corporation | $24.28 | 2025 | |
| Leadiant Biosciences, INC. | $22.86 | 2025 | Cystaran |
| Apellis Pharmaceuticals, INC. | $15.74 | 2025 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chetana Rondla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.